Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4620602 | 0.91 | CAPN1 (0.69) | CAPN1CAPNS1 | |
| SCHEMBL4622656 | 0.91 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL4622428 | 0.88 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL4620449 | 0.88 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL4620910 | 0.88 | CAPN1 (0.82) | CAPN1CAPNS1 | |
| SCHEMBL4622187 | 0.86 | CAPN1 (0.80) | CAPN1CAPNS1 | |
| SCHEMBL4622691 | 0.84 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL4623222 | 0.83 | CAPN1 (0.87) | CAPN1CAPNS1 | |
| SCHEMBL4621922 | 0.83 | CAPN1 (1.00) | CAPN1CAPNS1 | |
| SCHEMBL4621916 | 0.83 | CAPN1 (1.00) | CAPN1CAPNS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465721-B2 | 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-16 | — | — | US | claimed |
| EP-1701974-B1 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOD CONSEILS RECH APPLIC (FR) | 2008-03-26 | — | — | EP | claimed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | claimed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | claimed |
| US-7465721-B2 | 2-hydroxytetrahydrofuran derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-12-16 | — | — | US | disclosed |
| US-7384933-B2 | Derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-06-10 | — | — | US | disclosed |
| EP-1701974-B1 | NOVEL 2-HYDROXYTETRAHYDROFURANE DERIVATIVES AND USE THEREOF AS MEDICAMENTS | SOD CONSEILS RECH APPLIC (FR) | 2008-03-26 | — | — | EP | disclosed |
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2006-07-27 | — | — | US | disclosed |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | IPSEN PHARMA S.A.S. (FR) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166893-A1 | Novel 2-hydroxytetrahydrofurane derivatives and use thereof as medicaments | CAPN2, CAPN1, CAPNS1 | CAPN1 2/4885CAPNS1 3/4885 |
| US-20050222045-A1 | Novel derivatives of 2-hydroxytetrahydrofuran and their use as medicaments | CAPN1, MYH10, CAPN9 | CAPN1 1/4885CAPNS1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.